Pharmacodynamic Interaction between TAK-442, an Oral Direct Factor Xa Inhibitor, and Prasugrel in Healthy Subjects

Next Previous
Trial Profile

Pharmacodynamic Interaction between TAK-442, an Oral Direct Factor Xa Inhibitor, and Prasugrel in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2011

At a glance

  • Drugs Letaxaban; Prasugrel
  • Indications Acute coronary syndromes; Sickle cell anaemia; Thromboembolism
  • Focus Pharmacodynamics

    • Most Recent Events

    • 20 Apr 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top